医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集
▼×

腫瘍学

Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States

Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States

バイオテクノロジーヘルスケア感染症腫瘍学臨床試験製薬　 TimeLine: Infliximab-abda Now Available in the United States Samsung Bioepis Announces RENFLEXIS

2017年07月24日

0

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Research Milestone in Bispecific Antibody Zymeworks and Daiichi Sankyo Announce Successful

2017年07月18日

0

Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Abzena and Telix Sign Licence Agreement for Membrane Antigen Antibodies

2017年07月18日

0

Moving Mountains for Multiple Myeloma Program to Take on Fourth Continent with Climb to Mount Fuji

Moving Mountains for Multiple Myeloma Program to Take on Fourth Continent with Climb to Mount Fuji

腫瘍学　 TimeLine: Continent with Climb to Mount Fuji Moving Mountains for Multiple Myeloma Program

2017年07月13日

0

Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society

Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society

バイオテクノロジーヘルスケア放射線学腫瘍学製薬　 TimeLine: Annual International Conference of the IEEE Biology Society Data on Delivery of Tumor Treating Fields

2017年07月11日

0

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Combination with CABOMETYX Exelixis and Bristol-Myers Squibb Initiate Phase 3 Metastatic Renal Cell Carcinoma or Opdivo and Yervoy Versus Sunitinib in Previously Untreated Advanced

2017年07月10日

0

Solasia Announces Approval of episil® (oral liquid) in Japan

Solasia Announces Approval of episil® (oral liquid) in Japan

バイオテクノロジーヘルスケア医療機器歯科腫瘍学臨床試験製薬　 TimeLine: Solasia Announces Approval of episil

2017年07月07日

0

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Celgene Corporation Enters Into Global Strategic Collaboration with BeiGene to Advance PD-1 Tumor Cancers

2017年07月06日

0

新基公司和百济神州在免疫肿瘤领域达成全球战略合作共同在实体肿瘤领域推进PD-1抑制剂项目

新基公司和百济神州在免疫肿瘤领域达成全球战略合作共同在实体肿瘤领域推进PD-1抑制剂项目

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: 共同在实体肿瘤新基公司和百济神州

2017年07月06日

0

Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors

バイオテクノロジーヘルスケア外科腫瘍学臨床試験製薬　 TimeLine: 120 mg Receives Japanese Approval for a of Gastro-Entero-Pancreatic Neuroendocrine Tumors

2017年07月03日

0